- Home
- MSB vs IMMX Comparison
MSB vs IMMX Comparison
Compare MSB & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | IMMX |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 306.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MSB | IMMX |
|---|---|---|
| Price | $39.73 | $5.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 51.7K | ★ 1.5M |
| Earning Date | 04-24-2026 | 11-07-2025 |
| Dividend Yield | ★ 17.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $20,785,076.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $31.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.55 | $1.34 |
| 52 Week High | $41.91 | $7.73 |
Technical Indicators
Market Signals| Indicator | MSB | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 65.71 | 46.12 |
| Support Level | $36.50 | $5.02 |
| Resistance Level | $41.91 | $5.58 |
| Average True Range (ATR) | 2.12 | 0.40 |
| MACD | 0.45 | -0.18 |
| Stochastic Oscillator | 82.90 | 14.50 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.